Advertisement

Topics

Aduro Biotech Announces First Patient Dosed In Phase II Clinical Trial Of CRS-207 In Combination With KEYTRUDA?? (Pembrolizumab) For The Treatment Of Patients With Previously Treated Malignant Pleural Mesothelioma

20:00 EDT 28 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Aduro Biotech Announces First Patient Dosed In Phase II Clinical Trial Of CRS-207 In Combination With KEYTRUDA?? (Pembrolizumab) For The Treatment Of Patients With Previously Treated Malignant Pleural Mesothelioma

NEXT ARTICLE

More From BioPortfolio on "Aduro Biotech Announces First Patient Dosed In Phase II Clinical Trial Of CRS-207 In Combination With KEYTRUDA?? (Pembrolizumab) For The Treatment Of Patients With Previously Treated Malignant Pleural Mesothelioma"

Advertisement
Quick Search
Advertisement
Advertisement